| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| OPERATING ACTIVITIES: | | | | | | | | |
| Net loss | -10.6 | -8.0 | -5.4 | -9.9 | -9.4 | -8.1 | -9.1 | -8.3 |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | |
| Depreciation and amortization | 1.0 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 |
| Amortization of deferred financing costs and debt discount | 0.1 | 0.1 | | 0.0 | 0.0 | 0.0 | | 0.0 |
| Interest expense recorded as additional revenue interest obligation or long-term debt | 0.8 | 0.8 | | | 0.7 | 0.7 | | |
| Stock-based compensation | 0.7 | 0.7 | 0.8 | 0.3 | 1.5 | 1.1 | 1.0 | 1.0 |
| Bad debt expense | 0.8 | | | | | | | |
| Losses associated with viable bone matrix recall and market withdrawal | 2.0 | | | | | | | |
| Changes in operating assets and liabilities: | | | | | | | | |
| Accounts receivable | 0.2 | -0.5 | 0.3 | -0.5 | -0.6 | 0.0 | -0.5 | 2.2 |
| Inventory | -0.2 | -1.0 | 0.1 | -0.5 | 0.2 | -0.3 | 0.3 | 0.5 |
| Receivables of FiberCel litigation costs | 2.0 | 2.9 | 3.4 | -17.2 | | | | |
| Prepaid expenses and other | 0.0 | 0.6 | -2.0 | 0.8 | 1.2 | -1.6 | -0.2 | 0.5 |
| Accounts payable and accrued expenses and other current liabilities | 2.1 | 0.4 | 0.9 | 2.7 | 1.8 | -0.5 | 1.0 | -1.1 |
| Obligations to tissue suppliers | -0.2 | -0.5 | -0.1 | 0.0 | 0.3 | 0.4 | -0.2 | 0.5 |
| Contingent liability for FiberCel litigation | -1.2 | -1.7 | -0.3 | 17.6 | | | | |
| Deferred revenue and other liabilities | | | | | | | | |
| Net cash used in operating activities | -2.4 | -5.2 | -5.2 | -5.5 | -3.3 | -7.4 | -6.4 | -3.1 |
| |
| INVESTING ACTIVITIES: | | | | | | | | |
| Expenditures for property, plant and equipment | -0.1 | -0.2 | -0.1 | -0.1 | -0.3 | 0.0 | 0.0 | -0.1 |
| Net cash used in investing activities | -0.1 | -0.2 | -0.1 | -0.1 | -0.3 | 0.0 | 0.0 | -0.1 |
| |
| FINANCING ACTIVITIES: | | | | | | | | |
| Additional issuance costs in connection with Private Placement | | | 10.2 | | | -0.1 | | |
| Net borrowings (repayments) under revolving line of credit | | | 4.0 | 14.5 | 0.3 | 1.4 | 2.8 | -0.9 |
| Deferred financing costs | | | | | | | | |
| Repayments of long-term debt | | | | -15.3 | -1.7 | -1.7 | -1.7 | -1.1 |
| Payments on revenue interest obligation | | | | -0.7 | -0.7 | -0.7 | -0.7 | -0.7 |
| Payments for taxes upon vesting of restricted stock units | 0.0 | | | -0.4 | | | | |
| Proceeds from sales of common stock through Employee Stock Purchase Plan | | 0.1 | | 0.1 | | 0.2 | | 0.2 |
| Net cash provided by (used in) financing activities | 0.0 | 0.1 | 14.3 | -2.8 | -2.1 | -0.9 | 14.2 | -2.5 |
| Net decrease in cash and restricted cash | -2.5 | -5.2 | 8.9 | -8.4 | -5.7 | -8.3 | 7.8 | -5.7 |
| |
| Supplemental Cash Flow and Non-Cash Financing Activities Disclosures: | | | | | | | | |
| Cash paid for interest | 0.5 | 0.6 | 0.4 | 3.9 | | 1.2 | 1.2 | 1.3 |